TG Therapeutics Inc
(NAS:TGTX)
$
30.1
-1.345 (-4.28%)
Market Cap: 4.69 Bil
Enterprise Value: 4.60 Bil
PE Ratio: 0
PB Ratio: 24.39
GF Score: 74/100 TG Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023 / 03:30PM GMT
Release Date Price:
$27
(+1.93%)
Chris Howerton
Jefferies - Analyst
All right, everybody. My name is Chris Howerton, part of the Jefferies biotechnology research team. Very excited to see everybody here for our healthcare conference this year and of course, to be hosting a fireside chat with one of the companies I cover, TG Therapeutics. Mike, thank you so much for joining us.
Michael Weiss
TG Therapeutics, Inc. - Chairman, President & CEO
Of course. Great to see you, Chris.
Questions & Answers
Chris Howerton
Jefferies - Analyst
Likewise. All right. So obviously, we've gotten to know each other fairly well over the last couple of years. But for those that maybe are uninitiated, what is the elevator pitch right now on TG?
Michael Weiss
TG Therapeutics, Inc. - Chairman, President & CEO
Yeah. So it doesn't have to be very long elevator ride either. So TG is a pretty straightforward company these days. We got our first drug approved in MS called BRIUMVI. That has been our focus for the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot